Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334152 · ClinicalTrials.gov registry record · Phase 3
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 515
- Enrollment target
- 20
- Study locations
NCT00334152: Completed Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative, sponsored by GlaxoSmithKline.
NCT00334152 is a Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative that has completed, run by GlaxoSmithKline. The registered enrollment target is 515 participants, above the 382-participant average among 10 other Postoperative Nausea and Vomiting trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334152, a Phase 3 study of Postoperative Nausea and Vomiting and Nausea and Vomiting, Postoperative, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 515 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Primary Outcome
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple. Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose. Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves"). Study participants who receive antiemetic
Conditions Studied
Interventions
- DRUG casopitant
Study Locations (20)
California
- GSK Investigational Site - Arcadia
- GSK Investigational Site - Glendale
- GSK Investigational Site - Laguna Hills
- GSK Investigational Site - Pasadena
Florida
- GSK Investigational Site - Boca Raton
- GSK Investigational Site - Melbourne
- GSK Investigational Site - Miami
- GSK Investigational Site - West Palm Beach
Alabama
- GSK Investigational Site - Fairhope
- GSK Investigational Site - Mobile
- GSK Investigational Site - Montgomery
New York
- GSK Investigational Site - Mineola
- GSK Investigational Site - New Hyde Park
- GSK Investigational Site - New York
Arkansas
- GSK Investigational Site - Little Rock
Illinois
- GSK Investigational Site - Chicago
Kansas
- GSK Investigational Site - Kansas City
Maryland
- GSK Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
What the finished NCT00334152 record still lists
NCT00334152 is an interventional study that assigns participants to a tested intervention. The registered 515 participants enrollment target is mid-sized for trials with a published cap, above the 382-participant average among 10 other Postoperative Nausea and Vomiting trials with a reported enrollment target (35% higher).
The record links to 2 conditions, with Postoperative Nausea and Vomiting appearing as the primary indexed condition, and to 1 intervention - of which casopitant is the first listed.
NCT00334152 names 20 study sites across 10 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00334152 about?
NCT00334152 is a clinical study titled "Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women". This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
What is the current status of trial NCT00334152?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 2006-03. Estimated completion is 2006-07.
What conditions does trial NCT00334152 study?
This clinical trial studies the following conditions: Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative.
What interventions are being tested in trial NCT00334152?
The interventions under investigation include: casopitant (DRUG).
Who is sponsoring clinical trial NCT00334152?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334152 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea and Vomiting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00334152's enrollment target sits among peer trials
515 3rd of 10 higher than 8 of 10 other Postoperative Nausea and Vomiting trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postoperative Nausea and Vomiting trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population
RECRUITING · Phase 3
-
Study of APD421 as PONV Treatment (Prior Prophylaxis)
COMPLETED · Phase 3
-
Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.
RECRUITING · NA
-
Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery
RECRUITING · Phase 2
-
Costs of Postoperative Nausea and Vomiting in Ambulatory Surgery Patients
COMPLETED
-
Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- NCT06804837 · 515 participants · NA
Implement and Test Visual Consent Template and Process
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia